放射治療市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、最終用戶、地區和競爭格局分類，2021-2031年

全球放射治療市場預計將從 2025 年的 68.1 億美元成長到 2031 年的 112.5 億美元，年複合成長率為 8.73%。

放射療法是一種臨床治療方法，旨在利用電離輻射破壞癌組織DNA並抑制細胞增殖，從而治癒或緩解癌症。其發展的主要促進因素包括全球癌症發生率上升以及人口老化加劇，老年人更容易罹患惡性腫瘤。此外，與暫時的技術進步不同，發展中地區醫療報銷範圍的擴大為市場擴張提供了根本性的結構性推動力。儘管存在這些有利條件，但放射療法系統的高昂實施和營運成本嚴重阻礙了其普及，尤其是在財政資源有限的市場。這種經濟限制進一步加劇了基礎設施供給與日益成長的患者需求之間的差距。例如，美國癌症協會預測，到2025年，美國將新增2,041,910例癌症病例，這凸顯了尋求經濟可行的解決方案以應對日益嚴重的疾病負擔的迫切需求。

市場促進因素

將人工智慧 (AI) 和機器學習 (ML) 整合到治療計劃和執行系統中，正從根本上改變市場格局，顯著提高治療精度並消除工作流程中的許多低效環節。這些技術能夠自動完成諸如勾畫輪廓和劑量計算等複雜任務，大幅縮短從診斷到開始治療的時間，並最大限度地減少人為錯誤。這種營運效率的提升對於處理大量患者的醫療機構至關重要，它能夠實現根據解剖結構變化即時調整的治療方案。 2025 年 9 月，GE 醫療報告稱，其 AI 輔助智慧放射治療 (iRT) 解決方案的早期採用者已從模擬到治療計劃的時間從 7 天縮短至僅 7 分鐘。這種效率的顯著提升正在推動傳統系統被 AI 平台所取代，並透過高價值設備的升級來促進市場成長。同時，新興市場和成熟市場政府對醫療基礎設施的支持和資金投入，也為擴大放射治療的覆蓋範圍提供了強力的推動力。公共部門投資日益著重於腫瘤學現代化和解決服務不足地區設備短缺問題，這直接刺激了直線加速器及相關軟體的採購活動。例如，2025年5月，英國政府確認投資7,000萬英鎊，在28家醫院安裝新的放射治療設備，旨在縮短候診名單並改善癌症治療。這筆資金的注入凸顯了國家層級支持在維持市場成長動能方面發揮的關鍵作用。此外，現有基礎設施也不斷擴建以滿足全球需求。截至2025年7月，Elekta已在全球部署了超過7,500套設備和軟體解決方案，這反映​​了放射學應用範圍的不斷擴大。

市場挑戰

先進放射治療系統相關的巨額投資和營運成本是全球放射治療市場成長的主要障礙。先進平台，尤其是線性加速器和質子治療系統，需要巨額資本投入，不僅包括初始購買成本，還包括專用基礎設施、持續維護和高技能人員。在資金有限的市場中，這些高進入門檻阻礙了醫療機構擴大服務能力以滿足患者數量的需求。因此，許多醫療機構無力更換老舊設備或擴建設施，直接阻礙了市場擴張所需的新技術的應用。報銷模式的縮減進一步加劇了這一財務負擔，導致用於證明這些高成本採購合理性的投資回報率不穩定。隨著營運收入的下降，維持先進放射治療部門的經濟可行性受到削弱，迫使醫療機構停止資本投資。美國放射腫瘤學會（ASTRO）指出，到2025年，聯邦醫療保險（Medicare）對放射腫瘤服務的醫師報銷額將減少約2.8%。這種財政削減造成了不利的經濟環境，阻礙了基礎設施建設，從而限制了市場彌合日益成長的全球癌症治療需求與供應之間不斷擴大的差距的能力。

市場趨勢

磁振造影導引直線加速器（線性加速器）的加速普及正在改變市場格局，其能夠在放射治療過程中即時可視化軟組織，這是傳統X光引導系統所不具備的功能。這項技術使臨床醫生能夠縮小切除範圍，並安全地提高靠近重要器官的腫瘤劑量，從而加速了其在高階學術醫療中心和專業癌症治療網路中的效用。越來越多的臨床試驗數據支持該療法的臨床應用價值，也證明了這些平台所需的大量資本投入是合理的。 2025年5月，Elekta公司公佈了ERECT試驗的初步結果，顯示磁振導航放射治療顯著提高了患者的生活品質，並將6個月時勃起功能障礙的發生率從傳統方法的21%降低至6%。同時，質子和碳離子治療基礎設施的擴展表明，在治療深部惡性腫瘤方面，粒子束療法正逐漸佔據主導地位，因為它具有更優異的劑量深度特性。儘管初始投資龐大，但由於這些設施在兒童和複雜成人病例中具有保護正常組織的優勢，因此持續獲得投資。隨著製造商成功地將訂單的大型設備訂單轉化為運作設施，這一領域持續成長，也印證了這些大型專案的經濟可行性。例如，IBA在2025年3月報告稱，其總銷售額年增7%，達到4.982億歐元。這一成長主要得益於該公司穩步推進並轉化其訂單的質子治療和加速器訂單。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球放射治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型（體外放射治療、近距離放射治療、全身放射線治療）
  • 依應用領域（頭頸癌、口腔癌、乳癌、攝護腺癌、子宮頸癌、肺癌、其他）
  • 依最終使用者（醫院、研究機構、門診、放射治療中心）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美放射治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲放射治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區放射治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲放射治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲放射治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球放射治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Canon Medical Systems Corporation
• GE Healthcare Technologies Inc.
• Elekta AB
• ViewRay Technologies, Inc.
• Mevion Medical Systems Inc.
• BEBIG Medical GmbH
• Siemens Healthineers AG
• Accuray Incorporated
• Isoray Inc.
• Hitachi, Ltd.
• ALCEN Group

第16章 策略建議

第17章：關於研究公司及免責聲明

The global radiotherapy market is projected to expand from USD 6.81 billion in 2025 to USD 11.25 billion by 2031, growing at an 8.73% CAGR. Radiotherapy, a clinical method, uses ionizing radiation to damage the DNA of cancerous tissues, inhibiting cellular replication for either curative or palliative outcomes. The primary drivers for this growth include a rising global incidence of oncological disorders and a demographic shift towards an aging population, which is more prone to malignancies. Additionally, expanding healthcare reimbursement coverage in developing regions offers a fundamental structural impetus for market broadening, distinct from transient technological shifts. Despite these positive conditions, the high acquisition and operational costs of radiation delivery systems significantly impede widespread adoption, especially in markets with limited financial resources. This economic constraint exacerbates the disparity between infrastructure supply and escalating patient demand; for instance, the American Cancer Society projects 2,041,910 new cancer cases in the United States in 2025, emphasizing the critical need for economically viable solutions to address the increasing disease burden.

Market Driver

The integration of Artificial Intelligence (AI) and Machine Learning (ML) into treatment planning and delivery systems is fundamentally reshaping the market by enhancing therapeutic precision and addressing critical workflow inefficiencies. These technologies automate complex tasks like contouring and dose calculation, substantially reducing the time from diagnosis to treatment initiation while minimizing human error. Such operational acceleration is crucial for clinics managing high patient volumes, allowing for adaptive therapies that adjust to real-time anatomical changes. GE HealthCare reported in September 2025 that early adopters of their AI-supported Intelligent Radiation Therapy (iRT) solution reduced the time from simulation to treatment planning from seven days to just seven minutes. These dramatic efficiency gains are driving the replacement of legacy systems with AI-enabled platforms, thus fostering market growth through high-value equipment upgrades. Concurrently, supportive government initiatives and funding for healthcare infrastructure in both emerging and established markets serve as a robust catalyst for expanding radiotherapy accessibility. Public sector investment increasingly targets the modernization of oncology departments and bridging equipment gaps in underserved regions, directly stimulating procurement activities for linear accelerators and associated software. For example, the UK Government confirmed a £70 million investment in May 2025 to roll out new radiotherapy machines across 28 hospitals, aiming to cut waiting lists and improve cancer care. This capital injection highlights the vital role of state-level support in sustaining market momentum. Furthermore, the existing infrastructure continues to grow to meet global demand; Elekta, in July 2025, maintained an installed base of over 7,500 devices and software solutions worldwide, reflecting the expanding footprint of radiation medicine.

Market Challenge

The substantial acquisition and operational costs associated with advanced radiation delivery systems represent a significant barrier impeding the growth of the global radiotherapy market. Sophisticated platforms, particularly linear accelerators and proton therapy units, require immense capital expenditure that goes beyond the initial purchase, including specialized infrastructure, continuous maintenance, and highly skilled personnel. In markets with limited financial resources, this high barrier to entry prevents healthcare providers from scaling their capabilities to match patient volume. Consequently, many facilities cannot upgrade aging equipment or expand their footprint, directly stifling the adoption of newer technologies essential for market expansion. This financial strain is further intensified by contracting reimbursement models, which destabilize the return on investment necessary to justify such high-value procurements. When operational revenue declines, the economic viability of maintaining a state-of-the-art radiotherapy department is compromised, causing providers to halt capital investments. The American Society for Radiation Oncology noted a finalized Medicare Physician Fee Schedule reimbursement reduction of approximately 2.8 percent for radiation oncology services in 2025. Such fiscal contractions create an unfavorable economic environment that hinders infrastructure development, thereby restricting the market's ability to bridge the widening gap between supply and the escalating global demand for cancer care.

Market Trends

The accelerated adoption of MRI-Guided Linear Accelerators is transforming the market by enabling real-time visualization of soft tissue during radiation delivery, a capability absent in conventional X-ray guided systems. This technology allows clinicians to reduce margins and safely escalate doses to tumors located near critical organs, driving procurement in high-end academic centers and specialized oncology networks. The clinical validity of this modality is increasingly supported by robust trial data, which justifies the high capital investment required for these platforms. Elekta reported in May 2025 that preliminary results from the ERECT trial demonstrated that MR-guided radiotherapy significantly preserved patient quality of life, reducing the incidence of erectile dysfunction at six months to 6% compared to 21% with conventional methods. Parallel to this, the expansion of Proton and Carbon Ion Therapy infrastructure signifies a shift toward particle-based modalities, which offer superior depth-dose characteristics for treating deep-seated malignancies. Despite the substantial initial capital requirements, the market is witnessing sustained investment in these facilities, driven by their ability to spare healthy tissue in pediatric and complex adult cases. This segment is growing as manufacturers successfully convert heavy equipment order backlogs into operational centers, validating the economic feasibility of these massive projects. IBA, for instance, reported in March 2025 a 7% year-over-year increase in total net sales to €498.2 million, a growth trajectory largely sustained by the strong execution and conversion of its proton therapy and accelerator backlog.

Key Market Players

• Canon Medical Systems Corporation
• GE Healthcare Technologies Inc.
• Elekta AB
• ViewRay Technologies, Inc.
• Mevion Medical Systems Inc.
• BEBIG Medical GmbH
• Siemens Healthineers AG
• Accuray Incorporated
• Isoray Inc.
• Hitachi, Ltd.
• ALCEN Group

Report Scope

In this report, the Global Radiotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Radiotherapy Market, By Type

• External Beam Radiation Therapy
• Internal Radiation Therapy
• Systemic Radiation Therapy

Radiotherapy Market, By Application

• kin & Lip Cancer
• Breast Cancer
• Prostate Cancer
• Cervical Cancer
• Lung Cancer
• Others

Radiotherapy Market, By End-User

• Hospitals
• Research Institutes
• Ambulatory
• Radiotherapy Centers

Radiotherapy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Radiotherapy Market.

Available Customizations:

Global Radiotherapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Radiotherapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (External Beam Radiation Therapy, Internal Radiation Therapy, Systemic Radiation Therapy)
  • 5.2.2. By Application (kin & Lip Cancer, Breast Cancer, Prostate Cancer, Cervical Cancer, Lung Cancer, Others)
  • 5.2.3. By End-User (Hospitals, Research Institutes, Ambulatory, Radiotherapy Centers)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Radiotherapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Radiotherapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Radiotherapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Radiotherapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-User

7. Europe Radiotherapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Radiotherapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-User
  • 7.3.2. France Radiotherapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-User
  • 7.3.3. United Kingdom Radiotherapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Radiotherapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Radiotherapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-User

8. Asia Pacific Radiotherapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Radiotherapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Radiotherapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan Radiotherapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea Radiotherapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Radiotherapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End-User

9. Middle East & Africa Radiotherapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Radiotherapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-User
  • 9.3.2. UAE Radiotherapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-User
  • 9.3.3. South Africa Radiotherapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-User

10. South America Radiotherapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Radiotherapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-User
  • 10.3.2. Colombia Radiotherapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-User
  • 10.3.3. Argentina Radiotherapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Radiotherapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Canon Medical Systems Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. GE Healthcare Technologies Inc.
• 15.3. Elekta AB
• 15.4. ViewRay Technologies, Inc.
• 15.5. Mevion Medical Systems Inc.
• 15.6. BEBIG Medical GmbH
• 15.7. Siemens Healthineers AG
• 15.8. Accuray Incorporated
• 15.9. Isoray Inc.
• 15.10. Hitachi, Ltd.
• 15.11. ALCEN Group

16. Strategic Recommendations

17. About Us & Disclaimer